Isai joined MedImmune Ventures in 2010. He is currently or has been a board member of Adheron Therapeutics (acquired by Roche), Ambit (NASDAQ: AMBI, acquired by Daiichi Sankyo), Armaron Biosciences, Corridor Pharmaceuticals (acquired by Astrazeneca), Inotek Pharmaceuticals (NASDAQ:ITEK), and Xencor (NASDAQ: XNCR). He serves on The Ivy Foundation Biomedical Innovation Review Board at University of Virginia. Previously, Isai worked as a venture capitalist at Visium Asset Management. He was an investment banker at J.P. Morgan and a Specialty Pharmaceuticals analyst at Alliance Bernstein. Prior to Wall Street, Isai was a management consultant in the pharmaceutical and biotech industry; he began his career as a scientist at Merck. Isai is a graduate of Emory University where he earned a B.A. in Chemistry summa cum laude, and earned his M.B.A. from the Tuck School of Business at Dartmouth.